On 11/16/23, MEI Pharma Inc (NASDAQ: MEIP) stock suffered a major decline of -21.7%, closing at $6.14. The stock has declined -15.0% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
MEIP is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
MEI Pharma has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. MEI Pharma has a very low Appreciation Score of 8 but a very high Power Rating of 92, leading to the Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment